PremiumThe Fly89bio reports Q1 EPS (49c), consensus (57c) 89bio assumed with an Overweight at Cantor Fitzgerald 89bio Updates on Pegozafermin Clinical Progress PremiumThe Fly89bio price target lowered to $21 from $29 at H.C. Wainwright 89bio reports Q4 EPS ($1.02), consensus (76c) ETNB Insider Trade Alert! Majority Shareholder Buys $50M Worth of 89bio Stock PremiumThe Fly89bio price target raised to $38 from $25 at UBS, says shares ‘undervalued’ Biotech Alert: Searches spiking for these stocks today Akero upgraded to Buy at BofA after ‘transformative’ liver data 
